Lowest Price Guaranteed From USD 4,799
Published
September 2022
Pages
245
View Count
10029
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
The global antiviral drugs market is projected to grow from USD 57 billion in 2022 to USD 127 billion by 2035, exhibiting a CAGR of 6.3% during forecast period
Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide. In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. Further, it has been reported that human immunodeficiency virus (HIV) is anticipated to be the cause for 6.5 million deaths globally, by 2030. Over the past few years, a number of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally. However, it is important to note that, currently, the approved antiviral drugs (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life-threatening infectious diseases in humans. Further, several antiviral drugs are being evaluated across multiple clinical trials for the treatment of various infectious diseases. Moreover, post the onset of the COVID-19 pandemic, extensive research is being conducted to evaluate the safety and efficacy of novel antiviral therapeutics.
The antiviral therapeutic development is fraught with several challenges, including emergence of drug resistance in viruses (as viruses can frequently mutate their genome) and concerns related to drug safety and efficacy. In order to address the aforementioned concerns, several industry stakeholders have been actively leading the R&D efforts for the development of effective antiviral therapeutics against the known viral targets. The COVID-19 pandemic also exposed the lack of effective antiviral therapeutics that can be used for the treatment of re-emerging or emerging viral diseases; this has created opportunities for the development of novel antiviral drugs that can be effective against multiple viruses. Presently, more than 375 companies are engaged in the development of over 420 early and late-stage antiviral drugs, worldwide. These stakeholders have established multiple partnerships and collaborations in order to advance the development of various pipeline candidates. Moreover, in order to fund product development initiatives in this domain, various private and public sector investors have invested around USD 5.5 billion across multiple instances. Driven by the increasing demand for safe and effective antivirals, ongoing pace of innovation in this field, recent partnership activity and sufficient financial support from investors, the antiviral drugs market is anticipated to witness substantial growth in the mid to long-term.
Several recent developments have taken place in the field of antiviral drugs. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Antiviral Drugs Market, 2022-2035: Distribution by Mechanism of Action (Fusion Inhibitors, DNA Polymerases, Protease Inhibitors, Reverse Transcriptase Inhibitors and Others), Target Indication (Human Immunodeficiency virus Infection,Coronavirus Infection, Hepatitis, Herpes Simplex Virus Infection, Cytomegalovirus Infection, Influenza, and Others), Type of Drug Target (Virus Targets and Host Targets), Type of Therapy (Monotherapy and Combination Therapy) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current market landscape and future potential of the antiviral drugs market. The study also includes an in-depth analysis, highlighting the capabilities of antiviral drug developers engaged in this domain. Amongst other elements, the report features:
One of the key objectives of the report was to evaluate the current market size and the future potential associated with the antiviral drugs market, over the coming decades. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as mechanism of action (fusion inhibitors, DNA polymerases, protease inhibitors, reverse transcriptase inhibitors and others), target indication (human immunodeficiency virus infection,coronavirus infection, hepatitis, herpes simplex virus infection, cytomegalovirus infection, influenza, and others), type of drug target (virus targets and host targets), type of therapy (monotherapy and combination therapy) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.
Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Antiviral Drugs
3.2. Types of Viruses and Viral Diseases
3.3. Mechanism of Action of Antiviral Drugs
3.4. Characteristics of Antiviral Drugs
3.5. Advantages of Antiviral Drugs
3.6. Challenges Associated with Development of Antiviral Drugs
3.7. Key Facts and Future Perspectives of Antiviral Drugs
4. MARKET LANDSCAPE: APPROVED ANTIVIRAL DRUGS
4.1. Approved Antiviral Drugs: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Type of Dosage Form
4.1.3. Analysis by Type of Molecule
4.1.4. Analysis by Type of Target Virus
4.1.5. Analysis by Route of Administration
4.1.6. Analysis by Dosing Frequency
4.1.7. Analysis by Target Indication
4.1.8. Analysis by Mechanism of Action
4.2. Approved Antiviral Drugs: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography (Region-wise)
4.2.4. Analysis by Geography (Country-wise)
4.2.5. Most Active Players: Analysis by Number of Approved Drugs
5. MARKET LANDSCAPE: CLINICAL ANTIVIRAL DRUGS
5.1. Clinical-stage Antiviral Drugs: Overall Market Landscape
5.1.1. Analysis by Phase of Development
5.1.2. Analysis by Type of Molecule
5.1.3. Analysis by Phase of Development and Type of Molecule
5.1.4. Analysis by Type of Dosage Form
5.1.5. Analysis by Route of Administration
5.1.6. Analysis by Target Indication
5.1.7. Analysis by Phase of Development and Target Indication
5.1.8. Analysis by Type of Developer
5.1.9. Analysis by Type of Therapy
5.1.10. Analysis by Target Patient Segment
5.1.11. Analysis by Mechanism of Action
5.1.12. Analysis by Type of Target Virus
5.1.13. Analysis by Number of Doses
5.2. Clinical-Stage Antiviral Drugs: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography (Region-wise)
5.2.4. Analysis by Geography (Country-wise)
5.2.5. Analysis by Company Size and Location of Headquarters
5.2.6. Most Active Players: Analysis by Number of Clinical-Stage Drugs
6. COMPANY PROFILES
6.1. AbbVie
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments and Future Outlook
6.2. AstraZeneca
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments and Future Outlook
6.3. Bristol-Myers Squibb
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments and Future Outlook
6.4. Genentech
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Gilead Sciences
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments and Future Outlook
6.6. GlaxoSmithKline (GSK)
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments and Future Outlook
6.7. Johnson & Johnson
6.7.1. Company Overview
6.7.2. Key Executives
6.7.3. Financial Information
6.7.4. Product Portfolio
6.7.5. Recent Developments and Future Outlook
6.8. Merck
6.8.1. Company Overview
6.8.2. Key Executives
6.8.3. Financial Information
6.8.4. Product Portfolio
6.8.5. Recent Developments and Future Outlook
6.9. Novartis
6.9.1. Company Overview
6.9.2. Key Executives
6.9.3. Financial Information
6.9.4. Product Portfolio
6.9.5. Recent Developments and Future Outlook
6.10. Pfizer
6.10.1. Company Overview
6.10.2. Key Executives
6.10.3. Financial Information
6.10.4. Product Portfolio
6.10.5. Recent Developments and Future Outlook
6.11. Roche
6.11.1. Company Overview
6.11.2. Key Executives
6.11.3. Financial Information
6.11.4. Product Portfolio
6.11.5. Recent Developments and Future Outlook
6.12. ViiV Healthcare
6.12.1. Company Overview
6.12.2. Key Executives
6.12.3. Product Portfolio
6.12.4. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Antiviral Drugs: Partnerships and Collaborations
7.1.1. Analysis by Year of Partnership
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Target Indication
7.1.5. Analysis by Type of Target Virus
7.1.6. Analysis by Type of Partner
7.1.7. Most Active Players: Analysis by Number of Partnerships
7.1.8. Geographical Analysis
7.1.8.1. Intercontinental and Intracontinental Deals
7.1.8.2. International and Local Deals
8. FUNDING AND INVESTMENTS
8.1. Antiviral Drugs: Funding and Investments
8.1.1. Analysis by Year of Funding
8.1.2. Analysis of Amount Invested by Year
8.1.3 Analysis by Type of Funding
8.1.4. Analysis of Amount Invested by Type of Funding
8.1.5. Analysis by Target Indication
8.1.6. Analysis by Type of Target Virus
8.1.7. Analysis by Type of Investor
8.1.8. Most Active Players: Analysis by Number of Instances
8.1.9. Most Active Players: Analysis by Amount Invested
8.1.10. Most Active Investors: Analysis by Number of Instances
8.1.11. Geographical Analysis
8.1.11.1. Analysis of Amount Invested by Region
8.1.11.2. Analysis of Amount Invested by Country
9. PORTER’S FIVE FORCES ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Porter’s Five Forces
9.3.1. Threat of New Entrants
9.3.2. Bargaining Power of End Users
9.3.3. Bargaining Power of Drug Developers
9.3.4. Threat of Substitute Products
9.3.5. Rivalry Among Existing Competitors
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Forecast Methodology and Key Assumptions
10.2. Global Antiviral Drugs Market, 2022-2035
10.2.1. Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035
10.2.1.1. Antiviral Drugs Market for Fusion Inhibitors, 2022-2035
10.2.1.2. Antiviral Drugs Market for DNA Polymerases, 2022-2035
10.2.1.3. Antiviral Drugs Market for Protease Inhibitors, 2022-2035
10.2.1.4. Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035
10.2.1.5. Antiviral Drugs Market for Other Mechanisms, 2022-2035
10.2.2. Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035
10.2.2.1. Antiviral Drugs Market for Human Immunodeficiency Virus Infection, 2022-2035
10.2.2.2. Antiviral Drugs Market for Hepatitis, 2022-2035
10.2.2.3. Antiviral Drugs Market for Coronaviruses Infection, 2022-2035
10.2.2.4. Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035
10.2.2.5. Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035
10.2.2.6. Antiviral Drugs Market for Influenza, 2022-2035
10.2.2.7. Antiviral Drugs Market for Other Target Indications, 2022-2035
10.2.3. Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035
10.2.3.1. Antiviral Drugs Market for Virus Targets, 2022-2035
10.2.3.2. Antiviral Drugs Market for Host Targets, 2022-2035
10.2.4. Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035
10.2.4.1. Antiviral Drugs Market for Monotherapy, 2022-2035
10.2.4.2. Antiviral Drugs Market for Combination Therapy, 2022-2035
10.2.5. Antiviral Drugs Market: Distribution by Geography, 2022 and 2035
10.2.5.1. Antiviral Drugs Market in North America, 2022-2035
10.2.5.2. Antiviral Drugs Market in Europe, 2022-2035
10.2.5.3. Antiviral Drugs Market in Asia-Pacific, 2022-2035
10.2.5.4. Antiviral Drugs Market in Latin America, 2022-2035
10.2.5.5. Antiviral Drugs Market in MENA, 2022-2035
10.2.5.6. Antiviral Drugs Market in Rest of the World, 2022-2035
11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Pardes Biosciences
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Sean Brusky, Chief Commercial Officer
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape of Approved Antiviral Drugs
Figure 2.2 Executive Summary: Overall Market Landscape of Clinical-stage Antiviral Drugs
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Viruses
Figure 3.2 Mechanism of Action of Antiviral Drugs
Figure 4.1 Approved Antiviral Drugs: Distribution by Year of Approval
Figure 4.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Figure 4.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Figure 4.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Figure 4.5 Approved Antiviral Drugs: Distribution by Route of Administration
Figure 4.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Figure 4.7 Approved Antiviral Drugs: Distribution by Target Indication
Figure 4.8 Approved Antiviral Drugs: Distribution by Mechanism of Action
Figure 4.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 4.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Figure 4.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 4.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 4.13 Most Active Players: Distribution by Number of Approved Drugs
Figure 5.1 Clinical Antiviral Drugs: Distribution by Phase of Development
Figure 5.2 Clinical Antiviral Drugs: Distribution by Type of Molecule
Figure 5.3 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Figure 5.4 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Figure 5.5 Clinical Antiviral Drugs: Distribution by Route of Administration
Figure 5.6 Clinical Antiviral Drugs: Distribution by Target Indication
Figure 5.7 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Figure 5.8 Clinical Antiviral Drugs: Distribution by Type of Developer
Figure 5.9 Clinical Antiviral Drugs: Distribution by Type of Therapy
Figure 5.10 Clinical Antiviral Drugs: Distribution by Target Patient Segment
Figure 5.11 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Figure 5.12 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Figure 5.13 Clinical Antiviral Drugs: Distribution by Number of Doses
Figure 5.14 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 5.15 Clinical Antiviral Drugs Developers: Distribution by Company Size
Figure 5.16 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 5.17 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 5.18 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Figure 5.19 Most Active Players: Distribution by Number of Clinical-Stage Drugs
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Target Indication
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Target Virus
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 7.9 Partnerships and Collaborations: International and Local Deals
Figure 8.1 Funding and Investments: Distribution by Year of Funding
Figure 8.2 Funding and Investments: Distribution of Amount Invested by Year
Figure 8.3 Funding and Investments: Distribution by Type of Funding
Figure 8.4 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 8.5 Funding and Investments: Distribution by Target Indication
Figure 8.6 Funding and Investments: Distribution by Type of Target Virus
Figure 8.7 Funding and Investments: Distribution by Type of Investor
Figure 8.8 Most Active Players: Distribution by Number of Instances
Figure 8.9 Most Active Players: Distribution by Amount Invested
Figure 8.10 Most Active Investors: Distribution by Number of Instances
Figure 8.11 Funding and Investments: Distribution of Amount Invested by Region
Figure 8.12 Funding and Investments: Distribution of Amount Invested by Country
Figure 9.1 Antiviral Drugs: Porter’s Five Forces Analysis
Figure 10.1 Global Antiviral Drugs Market, 2022-2035 (USD Billion)
Figure 10.2 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Figure 10.3 Antiviral Drugs Market for Fusion Inhibitors, 2022-2035 (USD Billion)
Figure 10.4 Antiviral Drugs Market for DNA Polymerases, 2022-2035 (USD Billion)
Figure 10.5 Antiviral Drugs Market for Protease Inhibitors, 2022-2035 (USD Billion)
Figure 10.6 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035 (USD Billion)
Figure 10.7 Antiviral Drugs Market for Other Mechanisms, 2022-2035 (USD Billion)
Figure 10.8 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Figure 10.9 Antiviral Drugs Market for Human Immunodeficiency Virus Infection, 2022-2035 (USD Billion)
Figure 10.10 Antiviral Drugs Market for Hepatitis, 2022-2035 (USD Billion)
Figure 10.11 Antiviral Drugs Market for Coronavirus Infection, 2022-2035 (USD Billion)
Figure 10.12 Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035 (USD Billion)
Figure 10.13 Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035 (USD Billion)
Figure 10.14 Antiviral Drugs Market for Influenza, 2022-2035 (USD Billion)
Figure 10.15 Antiviral Drugs Market for Other Target Indications, 2022-2035 (USD Billion)
Figure 10.16 Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035 (USD Billion)
Figure 10.17 Antiviral Drugs Market for Virus Targets, 2022-2035 (USD Billion)
Figure 10.18 Antiviral Drugs Market for Host Targets, 2022-2035 (USD Billion)
Figure 10.19 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Figure 10.20 Antiviral Drugs Market for Monotherapy, 2022-2035 (USD Billion)
Figure 10.21 Antiviral Drugs Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 10.22 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 10.23 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Figure 10.24 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Figure 10.25 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 10.26 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Figure 10.27 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Figure 10.28 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)
Table 4.1 List of Approved Antiviral Drugs
Table 4.2 List of Approved Antiviral Drug Developers
Table 5.1 List of Clinical-Stage Antiviral Drugs
Table 5.2 List of Clinical-Stage Antiviral Drug Developers
Table 6.1 AbbVie: Product Portfolio
Table 6.2 AbbVie: Recent Developments and Future Outlook
Table 6.3 AstraZeneca: Product Portfolio
Table 6.4 AstraZeneca: Recent Developments and Future Outlook
Table 6.5 Bristol-Myers Squibb: Product Portfolio
Table 6.6 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.7 Genentech: Product Portfolio
Table 6.8 Genentech: Recent Developments and Future Outlook
Table 6.9 Gilead Sciences: Product Portfolio
Table 6.10 Gilead Sciences: Recent Developments and Future Outlook
Table 6.11 GlaxoSmithKline: Product Portfolio
Table 6.12 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.13 Johnson & Johnson: Product Portfolio
Table 6.14 Johnson & Johnson: Recent Developments and Future Outlook
Table 6.15 Merck: Product Portfolio
Table 6.16 Merck: Recent Developments and Future Outlook
Table 6.17 Novartis: Product Portfolio
Table 6.18 Novartis: Recent Developments and Future Outlook
Table 6.19 Pfizer: Product Portfolio
Table 6.20 Pfizer: Recent Developments and Future Outlook
Table 6.21 Roche: Product Portfolio
Table 6.22 Roche: Recent Developments and Future Outlook
Table 6.23 ViiV Healthcare: Product Portfolio
Table 6.24 ViiV Healthcare: Recent Developments and Future Outlook
Table 7.1 Antiviral Drugs: List of Partnerships and Collaborations
Table 8.1 Antiviral Drugs: List of Funding and Investments
Table 12.1 Approved Antiviral Drugs: Distribution by Year of Approval
Table 12.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Table 12.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Table 12.5 Approved Antiviral Drugs: Distribution by Route of Administration
Table 12.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Table 12.7 Approved Antiviral Drugs: Distribution by Target Indication
Table 12.8 Approved Antiviral Drugs: Distribution by Mechanism of Action
Table 12.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Table 12.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.13 Most Active Players: Distribution by Number of Approved Drugs
Table 12.14 Clinical Antiviral Drugs: Distribution by Phase of Development
Table 12.15 Clinical Antiviral Drugs: Distribution by Type of Molecule
Table 12.16 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Table 12.17 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.18 Clinical Antiviral Drugs: Distribution by Route of Administration
Table 12.19 Clinical Antiviral Drugs: Distribution by Target Indication
Table 12.20 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Table 12.21 Clinical Antiviral Drugs: Distribution by Type of Developer
Table 12.22 Clinical Antiviral Drugs: Distribution by Type of Therapy
Table 12.23 Clinical Antiviral Drugs: Distribution by Target Patient Segment
Table 12.24 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Table 12.25 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Table 12.26 Clinical Antiviral Drugs: Distribution by Number of Doses
Table 12.27 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.28 Clinical Antiviral Drugs Developers: Distribution by Company Size
Table 12.29 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.30 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.31 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Table 12.32 Most Active Players: Distribution by Number of Clinical-stage Drugs
Table 12.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.36 Partnerships and Collaborations: Distribution by Target Indication
Table 12.37 Partnerships and Collaborations: Distribution by Type of Target Virus
Table 12.38 Partnerships and Collaborations: Distribution by Type of Partner
Table 12.39 Most Active Players: Distribution by Number of Partnerships
Table 12.40 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 12.41 Partnerships and Collaborations: International and Local Deals
Table 12.42 Funding and Investments: Distribution by Year of Funding
Table 12.43 Funding and Investments: Distribution of Amount Invested by Year
Table 12.44 Funding and Investments: Distribution of by Type of Fundings
Table 12.45 Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 12.46 Funding and Investments: Distribution by Target Indication
Table 12.47 Funding and Investments: Distribution by Type of Target Virus
Table 12.48 Funding and Investments: Distribution by Type of Investor
Table 12.49 Most Active Players: Distribution by Number of Instances
Table 12.50 Most Active Players: Distribution by Amount Invested
Table 12.51 Most Active Investors: Distribution by Number of Instances
Table 12.52 Funding and Investments: Distribution of Amount Invested by Region
Table 12.53 Funding and Investments: Distribution of Amount Invested by Country
Table 12.54 Global Antiviral Drugs Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.55 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Table 12.56 Antiviral Drugs Market for Fusion Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.57 Antiviral Drugs Market for DNA Polymerases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.58 Antiviral Drugs Market for Protease Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.59 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.60 Antiviral Drugs Market for Other Mechanisms, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.61 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Table 12.62 Antiviral Drugs Market for Human Immunodeficiency Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.63 Antiviral Drugs Market for Hepatitis, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.64 Antiviral Drugs Market for Coronavirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.65 Antiviral Drugs Market for Herpes Simplex Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.66 Antiviral Drugs Market for Cytomegalovirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.67 Antiviral Drugs Market for Influenza, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.68 Antiviral Drugs Market for Other Target Indications, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.69 Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035 (USD Billion)
Table 12.70 Antiviral Drugs Market for Virus Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.71 Antiviral Drugs Market for Host Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.72 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Table 12.73 Antiviral Drugs Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.74 Antiviral Drugs Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.75 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 12.76 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Table 12.77 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Table 12.78 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Table 12.79 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Table 12.80 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Table 12.81 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Source 1: https://www.thelancet.com/article/S0140-6736(21)02796-3/fulltext